insulin resistance glp-1 Agonist Effects on Glucagon Suppression GLP-1-based therapies for type 2

Dehydration represents a clinically significant risk for patients taking GLP-1 medications, particularly during the initial weeks of therapy or following dose increases when gastrointestinal side effects are most pronounced

Because these medications naturally slow down your digestive system, mild to moderate gastrointestinal side effects can occur, particularly when first starting

Glucagon-like peptide-1 (GLP-1) is a GI peptide that stimulates insulin secretion (similar to sulfonylureas)

And the regulatory environment for compounded GLP-1 medications is shifting in ways that could affect every Willow subscriber

Products assigned a boxed warning carry risks of severe harm or death

(26-28) Preclinical and clinical studies suggest that GLP-1 receptor agonists may improve surgical outcomes by reducing infection rates and postoperative complications